Abbott has received marketing authorization from the European Commission for the use of Humira as a treatment for moderate-to-severe plaque psoriasis. In one clinical trial, more than 80%  of patients taking Humira achieved skin clearance of 75%  or better and in another, almost three quarters of patients achieved 75% clearance. In both trials, nearly half of the patients taking HUMIRA achieved 90% clearance as early as 16 weeks into treatment. Psoriasis is the fifth approved indication for H...